43 results about "Focal adhesion" patented technology

The invention relates to the field of biomedicine and drug synthesis, in particular to compounds for targeted degradation of focal adhesion kinase (FAK) protein, pharmaceutically acceptable salts, hydrates, solvates or prodrugs of the compounds, preparation methods of the compounds and the pharmaceutically acceptable salts, hydrates, solvates or prodrugs, and application of the compounds as therapeutic agents, especially as FAK degradation agents. The structures of the compounds, and the geometric isomers or pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof are shown inthe specification. The compounds provided by the invention have a good degradation effect on FAK kinase, and can be used for preventing, treating or adjunctively treating various diseases related tothe expression or activity of FAK kinase.

The present invention provides compositions and methods for treating a tissue disorder associated with a response-to-injury process or proliferating cells in a mammal. These tissue disorders are associated with a novel cellular phenotype designated as “transition cells” which are described herein. This cellular phenotype is characterized in having an activated erk kinase signaling activity, a stimulated AP-1 binding activity, and at least one characteristic selected from the group consisting of: (a) increased podosome formation, (b) increased flux of intracellular or extracellular hyaluronans or hyaladherins, (c) increased expression of a hyaladherin, (d) an inability to form focal adhesions, (e) increased metalloproteinase activity, and (f) increased expression of a hyaladherin. Example tissue disorders include fibrosis, inflammation, degeneration and invasive disorders such as occur in cancerous cells. The methods provided herein include administering to the mammal, an effective amount of a composition that alters the activity of transition molecules within a cell Transition molecules are shown to be comprised of hyaladherins, hyaluronans and associated molecules that regulate the transitional phenotype. A novel cell culture comprising transition cells is also provided, as well as compositions comprising particular peptides, polypeptides, and antibodies that affect the transitional phenotype.

The invention provides a compound. The compound is a compound shown as a formula I or a stereoisomer, a geometric isomer, a tautomer, nitrogen oxide, hydrate, a solvate, a metabolic product, pharmaceutically acceptable salt or a prodrug thereof: X-Y-Z (formula I), wherein X represents a ligand of FAK protein, Z represents ligand of E3 ligase and Y represents a chain for connecting the X and the Z.

The present invention provides compositions and methods for treating a tissue disorder associated with a response-to-injury process or proliferating cells in a mammal. These tissue disorders are associated with a novel cellular phenotype designated as “transition cells” which are described herein. This cellular phenotype is characterized in having an activated erk kinase signaling activity, a stimulated AP-1 binding activity, and at least one characteristic selected from the group consisting of: (a) increased podosome formation, (b) increased flux of intracellular or extracellular hyaluronans or hyaladherins, (c) increased expression of a hyaladherin, (d) an inability to form focal adhesions, (e) increased metalloproteinase activity, and (f) increased expression of a hyaladherin. Example tissue disorders include fibrosis, inflammation, degeneration and invasive disorders such as occur in cancerous cells. The methods provided herein include administering to the mammal, an effective amount of a composition that alters the activity of transition molecules within a cell Transition molecules are shown to be comprised of hyaladherins, hyaluronans and associated molecules that regulate the transitional phenotype. A novel cell culture comprising transition cells is also provided, as well as compositions comprising particular peptides, polypeptides, and antibodies that affect the transitional phenotype.

The invention relates to a non-conducting focal adhesion material, comprising following components: (a) at least one epoxy resin of non siloxane epoxy resin, and the epoxy equivalent weight is larger than 150 g/ e and smaller than 3000 g/ e; (b) siloxane epoxy resin, with the content being 10- 30 wt% of that of (a), and the epoxy equivalent weight is between 250- 1500 g/ e; (c) imidazole or sclerosing agent of its derivative, with its content being 5- 15 wt% of the total weight of (a) and (b); (d) phenol compound catalyst, with the content being 1- 8 wt% of that of (a) and (b); (e) toughening agent, with the content being 5- 16 wt% of that of (a) and (b); and (f) organic solvent, with the content being 25- 55 wt5 of the total weight of (a) (b) (c) (d) and (e).

The present invention relates to an agent for use in selectively killing one or more senescent cells, wherein the agent is selected from the following: a cardiac glycoside or alglycone, a focal adhesion kinase (FAK) inhibitor, an HMG-CoA reductase inhibitor, JFD00244, Cyclosporine, Tyrphostin AG879, Cantharidin, Diphenyleneiodonium chloride, Rottlerin, 2,3-Dimethoxy-1,4-naphthoquinone, LY-367,265,Rotenone, Idarubicin, Dequalintum chloride, Vincristine, Nitazoxanide, Nitrofurazone, Temsirolimus, Eltrombopag, Adapalene, Azacyclonol, Enoxacin and Raltegravir, and pharmaceutically acceptable salts thereof. Another aspect relates to compounds for use in treating or preventing a senescence- associated disease or disorder, and methods relating thereto.

The invention discloses a yeast extract, oligopeptide-1 and acetyl hexapeptide-1 V-shaped face stock solution capable of enabling faces to be compact in skin. The yeast extract, oligopeptide-1 and acetyl hexapeptide-1 V-shaped face stock solution contains water, butanediol, glycerine, betaine, beta-glucan, a yeast extract, a bacillus fermentation product, oligopeptide-1,acetyl hexapeptide-1, a honey extract, a paeonia suffruticosa root extract, an arnica extract, an althea root extract, a tilia europaea flower extract, propylene glycol, hydroximic acid, glycerol caprylate, hydroxyacetophenone,DL-1,2-Hexanediol, Arabic gum, xanthan gum, glycerine, a wild soybean seed extract, sodium hyaluronate and ethylenediaminetetraacetic acid disodium salt. The yeast extract, oligopeptide-1 and acetylhexapeptide-1 V-shaped face stock solution contains various natural plant extract essence, is prepared from a pure traditional Chinese medicine formula, is free from any hormones, can provide nutrients for skin and muscle, can promote cell energy, can enable the skin to be compact, can strengthen skin cohesion, and can strengthen focal adhesion. The yeast extract, oligopeptide-1 and acetyl hexapeptide-1 V-shaped face stock solution is natural, mild, good in safety and notable in V-shaped face effect of enabling the skin to be compact.

The invention belongs to the field of organic chemistry and drug synthesis, and relates to pyrrolo[2,3-d]pyrimidine compounds and salts thereof. The compounds and salts thereof have a remarkable inhibiting effect on focal adhesion kinase, and can be used for preparing medicines for treating related diseases of the focal adhesion kinase, especially can be used for preparing medicines for treating related tumors with high expression of the focal adhesion kinase.

The present invention is directed to treating a subject suffering from a disorder mediated by cell proliferation, such as cancer, by administering a fragment of focal adhesion kinase family kinase-interacting proteins. This method can involve regulating tumor formation or tumor growth in the subject. In addition, the present invention relates to the use of these proteins for regulating G1 to S phase progression of a cell, regulating the expression of p21 in a cell, regulating the phosphorylation of retinoblastoma protein in a cell, regulating retinoblastoma protein/E2F transcription factor 1 complex formation in a cell, regulating detachment-induced apoptosis of a cell, and regulating anchorage-independent growth of a cell.

The invention relates to a novel pyrimidine anti-tumor compound and a preparation method and application thereof. The novel pyrimidine anti-tumor compound is a compound shown in a formula (I), wherein each substituted group in the formula (I) is defined in the description. The invention also relates to the compound shown in the formula (I) or a pharmaceutically acceptable salt thereof, or application of a medicine composition containing the compound in inhibiting focal adhesion kinase, further treating tumor diseases, and especially treating pancreatic cancers, lung cancers and breast cancers. The formula (I) is shown in the description.

The invention belongs to the field of natural medicines and in particular discloses application of galangin in inhibition of transcription and expression of an FAK (focal adhesion kinase) gene, inhibition of functions of FAK through phosphorylation, inhibition of cell adhesion, infiltration and migration and inhibition of tumour metastasis. The invention also relates to a galangin medicine prepared by adopting the conventional medicine preparation method, galangin can be combined with the conventional tumour treatment medicine and treatment method when being used, and treatment application is carried out by adopting the conventional oral, intravenous and intraperitoneal administration routes, so that a foundation is laid for further application of the galangin.

An embodiment of the invention provides an FAK-targeting compound as well as a preparation method and application of the compound. The compound has a structure as shown in a general formula (I) whichis described in the specification. The compound provided by the invention has high affinity with FAK, and can be used as a compound for targeting FAK. Furthermore, since the FAK-targeting compound provided by the invention has an inhibition effect on FAK, the FAK-targeting compound can be used for preparing tumor treatment medicines; Besides, after the FAK-targeting compound provided by the invention is subjected to radiochemical labeling, the FAK-targeting compound can be used as a tumor diagnosis imaging agent for preparing tumor diagnosis drugs. The FAK-targeting compound provided by the invention has the characteristics of good affinity, strong specificity and high selectivity, and has clinical application value.

The invention provides application of galactotetraose sulfate and derivatives thereof in preparation of drugs for resisting epithelial cell adhesion. The galactotetraose sulfate or the derivatives thereof are applied to the drugs for resisting the epithelial cell adhesion, or the galactotetraose sulfate or the derivatives thereof are applied to a functional food for resisting the epithelial cell adhesion. The galactotetraose sulfate can achieve target binding with focal adhesion kinas (FAK). In this way, the adhesion capability of epithelial cells is effectively inhibited.

Disclosed is a method of treating cancer, involving the administration of a therapeutically effective amount of an inhibitor of the epidermal growth factor receptor (EGFR) pathway and the integrin/focal adhesion kinase (FAK) pathway to a patient in need of such treatment, where the inhibitor comprises at least the first 94 amino acids of a Tinagl1 protein, any fragments with conservative substitution showing 90% or greater homology to amino acids 22-94 of a Tinagl1 protein, or a signaling peptide fused or attached to a fragment with conservative substitution showing 90% or greater homology to amino acids 22-94 of a Tinagl1 protein.